Am+Ros治疗冠心病合并高血压的疗效

Curative Effect of Am+Ros on Coronary Heart Disease with Hypertension

目的分析氨氯地平(简称Am)联合瑞舒伐他汀(简称Ros)治疗冠心病(简称CHD)合并高血压(简称HBP)的可行性。方法该研究方便选取2018年3月—2019年9月间来院治疗的133例CHD并HBP患者。以随机数字表分组后,A组67例行Am+Ros治疗,B组66例行Am单纯治疗。对比治疗可行性。结果A组的总有效率(95.52%)高于B组(84.85%),差异有统计学意义(χ^(2)=4.295,P=0.038)。血压疗效上,治疗后,A组的收缩压(简称SBP)值低于B组,差异有统计学意义(t=16.839,P<0.001);A组的舒张压(简称DBP)值低于B组,差异有统计学意义(t=20.077,P<0.001)。血脂疗效上,治疗后,A组的总胆固醇(简称TC)值低于B组,差异有统计学意义(t=18.833,P<0.001);A组的高密度脂蛋白(简称HDL-C)值高于B组,差异有统计学意义(t=2.068,P=0.041);A组的三酰甘油(简称TG)值低于B组,差异有统计学意义(t=6.728,P<0.001);A组的低密度脂蛋白(简称LDL-C)值低于B组,差异有统计学意义(t=7.721,P<0.001)。血管内皮功能疗效上,治疗后,A组的血清内皮素-1(简称ET-1)低于B组,差异有统计学意义(t=27.053,P<0.001);A组的一氧化氮(简称NO)低于B组,差异有统计学意义(t=5.743,P<0.001)。A组的不良反应率(5.97%)低于B组(18.18%),差异有统计学意义(χ^(2)=4.685,P=0.030)。结论为CHD并HBP患者行Am+Ros治疗可改善血脂与血压水平,恢复血管内皮功能,安全性好。

Objective To analyze the feasibility of amlodipine(abbreviated as Am)combined with rosuvastatin(abbreviated as Ros)in the treatment of coronary heart disease(abbreviated CHD)combined with hypertension(abbreviated HBP).Methods 133 patients were conveniently selected in the study with CHD and HBP who came to the hospital for treatment from March 2018 to September 2019.After grouping by random number table,67 patients in group A received Am+Ros treatment,and 66 patients in group B received Am simple treatment.Compared treatment feasibility.Results The total effective rate of group A(95.52%)was higher than that of group B(84.85%),the difference was statistically significant(χ^(2)=4.295,P=0.038).In terms of blood pressure efficacy,after treatment,the systolic blood pressure(abbreviated as SBP)value of group A was lower than that of group B(t=16.839,P<0.001);the diastolic blood pressure(abbreviated as DBP)value of group A was lower than that of group B,the difference was statistically significant(t=20.077,P<0.001).In terms of blood lipid efficacy,after treatment,the total cholesterol(TC)value of group A was lower than that of group B,the difference was statistically significant(t=18.833,P<0.001);the high density lipoprotein(HDL-C)value of group A was higher than that of group B(t=2.068,P=0.041);the triacylglycerol(TG)value of group A was lower than that of group B,the difference was statistically significant(t=6.728,P<0.001);the low density lipoprotein(LDL-C)value of group A was lower than Group B,the difference was statistically significant(t=7.721,P<0.001).In terms of the efficacy of vascular endothelial function,after treatment,the serum endothelin-1(abbreviated as ET-1)in group A was lower than that in group B,the difference was statistically significant(t=27.053,P<0.001);the nitric oxide(abbreviated as NO)in group A was lower than Group B,the difference was statistically significant(t=5.743,P<0.001).The adverse reaction rate of group A(5.97%)was lower than that of group B(18.18%),the difference was statistically significant(χ^(2)=4.685,P=0.030).Conclusion Am+Ros treatment for patients with CHD and HBP can improve blood lipid and blood pressure levels,restore vascular endothelial function,and is safe.